October 21, 2021
Ono Pharmaceutical said on October 20 that Taiwanese regulatory authorities have granted approval for a combination of its PD-1 inhibitor Opdivo (nivolumab) and chemotherapy for an additional indication to treat certain patients with gastric cancer, gastroesophageal junction cancer, and esophageal...read more